Roche Reports Strong H1 2026 Sales Growth and Multiple FDA Priority Reviews
Roche's pharmaceuticals division saw a 6% sales increase in H1 2026, driven by key products and multiple FDA Priority Reviews for new therapies.
Asset / Drug
Drug and asset intelligence for Enspryng with 14 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.